Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | STAT1 | P42224 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CTRC | Q99895 | 1/20 | 0.30 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3361342 | 0.81 | CTRC (0.33) | CTRC | |
| SCHEMBL1098786 | 0.74 | TDP1 (0.39) | TSHRMAPTPOLBHPGDCTRC | |
| SCHEMBL1515036 | 0.74 | CTRC (0.30) | CTRC | |
| SCHEMBL17372500 | 0.73 | ALOX5 (0.32) | ALDH1A1GAA | |
| SCHEMBL3370665 | 0.73 | — | — | |
| SCHEMBL14324289 | 0.71 | POLB (0.50) | ALDH1A1HTTL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL6389139 | 0.71 | GAA (0.47) | ALDH1A1HTTL3MBTL1GAATSHR | |
| SCHEMBL8635202 | 0.71 | ALDH1A1 (0.57) | ALDH1A1HTTL3MBTL1GAATSHR | |
| SCHEMBL1098333 | 0.70 | MEN1 (0.31) | — | |
| SCHEMBL625752 | 0.69 | ALDH1A1 (0.55) | ALDH1A1HTTL3MBTL1GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-8653096-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2012-02-23 | — | — | US | disclosed |
| US-8058287-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-7935688-B2 | Vitamin D-like compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20110060146-A1 | VITAMIN-D-LIKE COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-10 | — | — | US | disclosed |
| EP-2286811-A1 | Chemokine receptor antagonists and methods of use thereof | Millennium Pharmaceuticals, Inc. (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1523485-B1 | 3-FURANYL ANALOGS OF TOXOFLAVINE AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-14 | — | — | EP | disclosed |
| EP-1688418-A2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20060040943-A1 | 3-Furanyl analogs of toxoflavine as kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | US | disclosed |
| EP-1523485-A1 | 3-FURANYL ANALOGS OF TOXOFLAVINE AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-04-20 | — | — | EP | disclosed |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| WO-2004007499-A1 | 3-FURANYL ANALOGS OF TOXOFLAVINE AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-01-22 | — | — | WO | disclosed |
| US-20020169155-A1 | A nitrogen-ring containing triheterocyclic compound is useful for treating a disease associated with aberrant leukocyte recruitment and/or activation | MILLENNIUM PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | disclosed |
| EP-1204665-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | Millennium Pharmaceuticals, Inc. (US) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001009138-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-1998053790-A2 | COMPOUNDS THAT INHIBIT THE BINDING OF VASCULAR ENDOTHELIAL GROWTH FACTOR TO ITS RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040943-A1 | 3-Furanyl analogs of toxoflavine as kinase inhibitors | GRK3, GRK4, GRK6 | ALDH1A1 4096/4885HTT 1729/4885L3MBTL1 2989/4885 |
| US-20020169155-A1 | A nitrogen-ring containing triheterocyclic compound is useful for treating a disease associated with aberrant leukocyte recruitment and/or activation | NFATC1, ELANE, NCF1 | ALDH1A1 3606/4885HTT 3354/4885L3MBTL1 2042/4885 |
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | ACKR3, CCL11, CCR7 | ALDH1A1 2010/4885HTT 4366/4885L3MBTL1 3786/4885 |
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | ALDH1A1 2146/4885HTT 4355/4885L3MBTL1 4007/4885 |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | ALDH1A1 2146/4885HTT 4355/4885L3MBTL1 4007/4885 |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | ACKR3, CXCR2, CCL11 | ALDH1A1 1086/4885HTT 4583/4885L3MBTL1 4150/4885 |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | ALDH1A1 2146/4885HTT 4355/4885L3MBTL1 4007/4885 |
| US-20110060146-A1 | VITAMIN-D-LIKE COMPOUNDS | VDR, CYP24A1, CYP2R1 | ALDH1A1 3720/4885HTT 3767/4885L3MBTL1 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.